- Home
- KROS vs SEMR Comparison
KROS vs SEMR Comparison
Compare KROS & SEMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- SEMR
- Stock Information
- Founded
- KROS 2015
- SEMR 2008
- Country
- KROS United States
- SEMR United States
- Employees
- KROS N/A
- SEMR N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- SEMR EDP Services
- Sector
- KROS Health Care
- SEMR Technology
- Exchange
- KROS Nasdaq
- SEMR Nasdaq
- Market Cap
- KROS 1.8B
- SEMR 1.9B
- IPO Year
- KROS 2020
- SEMR 2021
- Fundamental
- Price
- KROS $56.62
- SEMR $13.37
- Analyst Decision
- KROS Strong Buy
- SEMR Buy
- Analyst Count
- KROS 8
- SEMR 7
- Target Price
- KROS $91.43
- SEMR $16.14
- AVG Volume (30 Days)
- KROS 383.1K
- SEMR 349.8K
- Earning Date
- KROS 11-06-2024
- SEMR 11-07-2024
- Dividend Yield
- KROS N/A
- SEMR N/A
- EPS Growth
- KROS N/A
- SEMR N/A
- EPS
- KROS N/A
- SEMR 0.08
- Revenue
- KROS $651,000.00
- SEMR $357,567,000.00
- Revenue This Year
- KROS $1,232.45
- SEMR $24.21
- Revenue Next Year
- KROS $126.39
- SEMR $19.41
- P/E Ratio
- KROS N/A
- SEMR $173.74
- Revenue Growth
- KROS 8037.50
- SEMR 22.01
- 52 Week Low
- KROS $27.31
- SEMR $9.43
- 52 Week High
- KROS $73.00
- SEMR $16.42
- Technical
- Relative Strength Index (RSI)
- KROS 38.94
- SEMR 47.71
- Support Level
- KROS $65.54
- SEMR $12.05
- Resistance Level
- KROS $70.26
- SEMR $14.47
- Average True Range (ATR)
- KROS 3.17
- SEMR 0.51
- MACD
- KROS -0.64
- SEMR 0.05
- Stochastic Oscillator
- KROS 9.07
- SEMR 54.50
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the provision of an online visibility management software-as-a-service platform. Its platform enables subscribers to improve their online visibility and drive traffic, including on their websites and social media pages, and distribute highly relevant content to their customers on a targeted basis across various channels to drive high-quality traffic and measure the effectiveness of their digital marketing campaigns. Geographically, it generates revenues from the US, the UK, and other regions.